Abiraterone-d4
Product Specifications
UNSPSC Description
Abiraterone-d4 is the deuterium labeled Abiraterone. Abiraterone is a potent and irreversible CYP17A1 inhibitor with antiandrogen activity, which inhibits both the 17α-hydroxylase and 17,20-lyase activity of the cytochrome p450 enzyme CYP17 with IC50s of 2.5 nM and 15 nM, respectively.
Target Antigen
Cytochrome P450
Type
Isotope-Labeled Compounds
Related Pathways
Metabolic Enzyme/Protease
Field of Research
Cancer
Purity
98.0
Solubility
Ethanol : 5 mg/mL (ultrasonic;warming)
Smiles
C[C@@]12C(C3=C([2H])N=C([2H])C([2H])=C3[2H])=CC[C@]1([C@@]4(CC=C5[C@@](C)([C@]4(CC2)[H])CC[C@@H](C5)O)[H])[H]
Molecular Weight
353.53
References & Citations
[1]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71.;Richards J, et al. Interactions of|[2]Attard G, et al. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol. 2008 Oct 1;26(28):4563-71.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture and light)
Clinical Information
No Development Reported
CAS Number
2122245-62-7
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items